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Abstract

Background: Limited data exist on the incidence and outcome of early infection after orthotopic heart transplantation (OHT). The purpose of this study was to describe characteristics and outcomes of OHT recipients
with an early infection and to identify predictors of such infections.
Methods: This retrospective, single-center study included patients greater than 18 years of age who underwent
OHT from February 2009 to May 2014 and had an infection within 30 days of transplantation. Patient
demographics, clinical variables, and outcomes were collected. Multivariable logistic regression was performed
to identify independent predictors of infection.
Results: Of the 172 eligible OHT recipients, 51 (29.7%) had an early infection. The median time to diagnosis
was five days, with gram-negative organisms being slightly more common (58.2%). No differences in mortality
rate, rejection, or re-admission were found between the groups. Longer durations of mechanical ventilation and
lengths of stay were found in the infection group (p < 0.001). Patients with an early infection also had a higher
incidence of mechanical circulatory support, history of drive-line infection, longer duration of mechanical
ventilation, continuous renal replacement therapy (CRRT), and delayed chest closure (p < 0.05 for all). PreOHT left-ventricular assist device (adjusted odds ratio [AOR] 2.53; 95% confidence interval [CI] 1.015–6.286;
p < 0.046), pre-OHT extracorporeal membrane oxygenation (AOR 14.10; 95% CI 1.38–150.5; p = 0.026) and
post-OHT CRRT (AOR 3.98; 95% CI 1.67–9.52; p = 0.002) were found to be independent risk factors for an
early infection. A total of 90% of the available susceptibility panels for the gram-negative isolates (26/29) were
resistant to the standard peri-operative cephalosporin given.
Conclusions: Prior mechanical circulatory support and the acute need for CRRT may predispose OHT patients
to an infection early in the post-operative period. Evaluation of peri-operative antimicrobial prophylaxis, based
on an individual center’s resistance panels, may be warranted.
Keywords: infection; left ventricular assist device; orthotopic heart transplantation

S

ince the first heart transplantation in 1967, the
procedure has grown worldwide to a total of 120,991
adult recipients as of June 2016 [1]. With advances in immunosuppression regimens and surgical technique, the overall
risk of rejection and survival have improved [2,3]. However,
infectious complications remain and may influence survival,
rejection, and re-admission rates.
According to the Scientific Registry of Transplant Recipients
(SRTR) and Organ Procurement and Transplantation Network

(OPTN) Annual Data Report in 2015, infection was the most
common cause of death (2.3% of the series) at one year after
OHT [2]. Infection within the first month post-OHT has demonstrated even higher mortality rates (13%–60%) in some
studies [4,5]. Bacterial infections continue to be the most common type of severe infections [4,6–9], with gram-positive organisms being the primary infecting pathogens [6]. Interest in blactamase-producing Enterobacteriaceae and fungal infections
in this patient population also has emerged recently [10–12].
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INFECTION AFTER HEART TRANSPLANTATION

Although the incidence and type of infection post-OHT
have been reported [1,2,4,5], the characteristics of patients
who develop infection in the early transplant period have not
been described well. Descriptions of the organisms cultured,
sites of infection, and risk factors contributing to these early
infections are lacking. Additionally, the impact of early infection on clinical outcomes is unclear. The purpose of this
study was to describe the characteristics and outcomes of
OHT recipients with an infection identified within 30 days of
transplantation. Secondary objectives were identifying factors associated with an early infection.

Downloaded by Washington Univ from www.liebertpub.com at 07/18/18. For personal use only.

Patients and Methods

This retrospective, single-center cohort study was performed at Barnes-Jewish Hospital, a 1,315-bed tertiary-care
academic medical center that is the affiliated teaching hospital for Washington University School of Medicine in St.
Louis. The Washington University School of Medicine Human Research Protection Office and the Protocol Review and
Monitoring Committee approved this study.
The Barnes-Jewish Hospital medical informatics system was
queried to identify OHT recipients who were admitted between
February 2009 and May 2014. To be included in the earlyinfection cohort, OHT recipients had to be at least 18 years of
age, have a positive culture with one or more organism(s), and
meet the specified definition of infection within 30 days posttransplant. Exclusion criteria included death within 48 hours of
transplant, missing data in the medical chart, transplant performed at an outside hospital, or active infection requiring intravenous antibiotics at the time of transplantation.
Electronic medical records were searched to identify
demographic data, immunosuppressive and antimicrobial
regimens received, site of positive culture(s), organism(s)
cultured, and time to first positive culture. Baseline comorbidities were identified via the International Classification of Disease 9th revision codes [13,14]. Hospital and
intensive care unit (ICU) length of stay (LOS), rejection
occurrence, re-admission dates, and mortality data also were
collected.
Definitions

All documented infections were confirmed on the basis of
clinical signs and symptoms of infection in correlation with a
positive culture and an infectious disease consultation when
applicable. Pneumonia was defined as the presence of new or
worsening radiographic pulmonary infiltrates along with
clinical findings suggesting infection (leukocytosis, fever,
purulent sputum) in addition to growth of organism(s) in
cultures obtained through sputum or tracheal aspirate, with
hospital-acquired pneumonia (HAP) occurring 48 hours or
more after admission and ventilator-associated pneumonia
(VAP) occurring 48 hours or more after endotracheal intubation. Nosocomial tracheobronchitis was defined when
clinical findings suggested a pulmonary infection with a
positive respiratory culture without a new lung infiltrate
[4,15]. Urinary tract infection (UTI) was diagnosed in patients without an indwelling urethral catheter when documentation of pyuria or bacteremia in addition to a positive
urine culture (>105 colony-forming units [CFU]/mL) was
found [4]. In patients with indwelling urethral catheters, ‡105
CFU/mL of one or more bacterial species in a urine specimen
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had to be noted [16]. Blood stream infection (BSI) was defined as one or more organisms isolated from at least two
consecutive blood cultures. In cases involving microorganisms of doubtful significance (e.g., Bacillus spp.,
coagulase-negative Staphylococcus spp.), clinically relevant
episodes were noted only if evidence of clinical infection was
present in addition to an infectious disease consultation diagnosis.
Multi-drug resistance (MDR) for Staphylococcus aureus,
Enterococcus spp., Enterobacteriaceae, Pseudomonas aeruginosa, and Acinetobacter spp. were defined according to
standardized terminology [17]. Our institution’s microbiology
laboratory reports susceptibility results of AmpC-stable blactamases as well as non-b-lactam agents for Enterobacter
spp., Serratia spp., and Citrobacter freundii. Default resistance
to AmpC-labile agents (ceftriaxone, aztreonam, piperacillin/
tazobactam) is reported for the aforementioned bacterial isolates, as at our center, 85% have inducible AmpC resistance
and 11% have stable high-level AmpC expression [18].
Appropriate antimicrobial therapy was defined as an initially prescribed regimen with activity against the identified
pathogen based on in vitro susceptibility testing and administration within 24 hours of culture. Acute cellular rejection
(ACR) was defined as a biopsy specimen post-OHT displaying Grade ‡2R/3a rejection [19].
Standard process of care

Peri-operative prophylaxis for OHT recipients includes
vancomycin and cefazolin intra-operatively, continued for
24 hours after chest closure. Heart transplant recipients at
our institution do not receive routine surveillance cultures
in the intra-operative or post-operative periods. Cultures
are obtained only when there is clinical evidence suggestive
of infection that may warrant treatment. Clinical evidence
of infection prompting an infectious work-up include fever,
leukocytosis, hypotension, and diagnostic imaging or other
hemodynamic measures suggestive of sepsis. Infectious
disease consultations generally are obtained on all transplant recipients. The current immunosuppression protocol
at Barnes-Jewish Hospital is methylprednisolone intraoperatively followed by mycophenolate mofetil ( MMF),
tacrolimus, and methylprednisolone immediately postoperatively. Patients who received induction therapy from
February 1, 2009 to August 2010 received anti-thymocyte
globulin and those operated on from August 2010 to May
2014 received basiliximab because of a change in institution
protocol. Patients received induction unless considered at
high risk for infection; i.e., on suppressive antibiotics prior
to transplantation.
Statistical analysis

Statistical analysis was completed using SPSS software,
version 22.0 (SPSS, Inc., Chicago, IL). Continuous data were
analyzed using the Student’s t-test for parametric data and
the Mann-Whitney U test for nonparametric data. Categorical
data were analyzed with the w2 or the Fisher exact test. A
p value <0.05 was considered significant. Backwards stepwise logistic regression was utilized to identify risk factors
independently associated with an early infection. Variables
significant at a p value £0.1 in the univariable analyses were
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A total of 185 OHTs were performed during the study
period. Thirteen patients were excluded, leaving 172 patients
for analysis. Early infection criteria were met in 51 patients
(29.7%) (Fig. 1). The majority of the patients were Caucasian
males, younger than 65 years, with an idiopathic cardiomyopathy diagnosis. A significantly higher percent of patients
in the early infection cohort received extracorporeal membrane oxygenation (ECMO) before OHT (11.8% vs. 0.8%;
p = 0.003), were left-ventricular assist device (LVAD) explants (66.7% vs. 30.6%; <0.001), and had histories of driveline infection (23.5% vs. 10.7%; p = 0.035) (Table 1). When
further analyzed by type of infection, no differences in demographic data were found.
No difference in induction therapy was noted between the
early-infection and no early-infection cohorts. The primary
agent utilized was basiliximab in both groups. All patients
received maintenance therapy with tacrolimus, MMF, and
steroids per protocol. Patients in the infection cohort had a
higher incidence of continuous renal replacement therapy
(CRRT) after OHT, delayed chest closure, ECMO after OHT,
and a longer duration of mechanical ventilation (p < 0.05)
(Table 2).

common organisms were Staphylococcus spp., Enterobacter
spp., and Escherichia coli. Twenty-four MDR pathogens
(47%) were identified (20 gram-negative, two methicillinresistant S. aureus, two vancomycin-resistant Enterococci).
The most prevalent infection was pneumonia (n = 24; 47%;
19 VAP, five HAP) followed by BSI (n = 0; 19.6%) and UTI
(n = 7; 13.7%). Other infections were ventricular-assist device (VAD) pocket (n = 3; 5.8%), tracheobronchitis (n = 2;
3.9%), Clostridium difficile diarrhea (n = 2), and mediastinitis, groin seroma, pericarditis, and pacemaker (n = 1 each;
2.0%). Of the 24 pneumonia episodes, the organisms most
often isolated were gram-negative species with a median time
to infection of 4.3 days. Of note, patients with pneumonia had
a longer median mechanical ventilation duration of 9.5 (IQR
5.4–15.7) days compared with 2.8 (IQR 0.7–5.1) days in the
patients with other sites of infection (p < 0.001). Additionally,
the median mechanical ventilation duration for patients with
pneumonia was significantly longer than for the non-infected
group (9.5 vs. 1.8 days; IQR 0.8–3.6 days; p < 0.0001). The most
common BSI organisms were Serratia marcescens (n = 3; 30%)
and Enterobacter cloacae (n = 2; 20%) with a median time to
infection of 5.3 days. Escherichia coli and Pseudomonas aeruginosa (n = 2; 28.6% each) were the most common UTI organisms with a median time to infection of nine days. The
median duration of mechanical ventilation prior to a diagnosis of
a non-respiratory infection was four days. This was not significantly different from those with a respiratory infection.

Early infection cohort

Antimicrobial therapy

The median temperature at the time of infection diagnosis
was 37.3C (interquartile range [IQR] 36.6–37.9C). Of note,
24 patients (47%) were on CRRT at the time of their infection
diagnosis, potentially masking the presence of a fever. The
median white blood cell (WBC) count at the time of infection
diagnosis was 23 · 103/mm3 (IQR 17.5–28.7 · 103/mm3).
The majority of patients (78.4%) were receiving at least one
vasopressor. The median time to infection diagnosis was
five days (IQR 2.1–8.7 d).
A total of 67 organisms were identified in the 51 patients
with an early infection (Table 3). The most prevalent organisms were gram-negative bacteria (n = 39; 58.2%) with
fewer gram-positive organisms (n = 20; 29.9%). The most

Standard peri-operative antimicrobial prophylaxis was administered to 75% of patients who sustained an early infection
when patient allergies or previous culture history did not cause
divergence. The remaining 25% received broader coverage
with linezolid in the case of vancomycin intolerance and aztreonam or meropenem for cephalosporin intolerance. Of
the 33 patients with gram-negative isolates, 29 (88%) had
susceptibility panels available for assessment. Notably, a total of 26 (90%) of the available susceptibility panels for the
gram-negative isolates, which included Citrobacter freundii,
Enterobacter spp., Escherichia coli, Klebsiella pneumoniae,
Proteus spp., Pseudomonas aeruginosa, and Serratia marcescens, showed resistance to cefazolin. The median time to

entered in the stepwise multivariable logistic regression
model.
Results
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FIG. 1. Adult orthotopic heart transplant (OHT) recipients from Barnes-Jewish Hospital were assessed for study inclusion. Based on the inclusion criteria, 172 patients were eligible for analysis, with 51 patients meeting the criteria for early
infection.
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Table 1. Baseline Characteristics of Early Infection Cohort vs. No Early Infection Cohorta
Early infection (n = 51)

Downloaded by Washington Univ from www.liebertpub.com at 07/18/18. For personal use only.

Variable
Race
Caucasian
African American
Asian
Native American
Age (y)b
>65
Male sex
Body Mass Index (kg/m2)b
‡35
Reason for orthotopic heart transplantation
Idiopathic
Ischemic cardiomyopathy
Valvular
Restrictive
Hypertrophic
Graft dysfunction
Co-morbidities
Coronary artery disease
Diabetes mellitus
Chronic obstructive pulmonary disease
Asthma
Prior ECMO during same hospitalization
Left-ventricular assist device (LVAD) explants
History of LVAD DL infection
Duration of antibiotic for DL infection (d)b

No early infection (n = 121)

p
0.284

35
16
0
0
53.9
9
37
28.4
8

( 68.6)
( 31.4)

30
12
5
2
2
0

( 58.8)
( 23.5)
( 9.8)
( 3.9)
( 3.9)

23
27
8
4
6
34
12
233.5

(
(
(
(
(

45–63)
17.6)
72.5)
24.2–32.4)
15.7)

( 45.1)
( 52.9)
( 15.7)
( 7.8)
( 11.8)
( 66.7)
( 23.5)
(153.5–705.25)

96
23
1
1
54.4
18
79
27.6
16

(79.3)
(19.0)
(0.8)
(0.8)
(48–62)
(14.9)
(65.3)
(22.8–30.9)
(13.2)

64
41
3
3
5
5

(52.9)
(33.9)
( 2.5)
( 2.5)
( 4.1)
( 4.1)

55
55
19
8
1
37
13
227

( 45.5)
(45.5)
(15.7)
( 6.6)
( 0.8)
(30.6)
(10.7)
(81–503.5)

0.873
0.648
0.353
0.289
0.670
0.157

0.966
0.369
0.998
0.751
0.003
<0.001
0.035
0.320

a

All values presented as n (%) unless otherwise noted.
Values presented as median (interquartile range).
DL = drive line; ECMO: extracorporeal membrane oxygenation.

b

positive culture in this group was 1.5 days. Overall, inappropriate antimicrobial treatment was noted in 12 patients
(24%).

tient in the no-infection group died of PGD. Rejection rates
were similar in the two groups. Patients with an early infection had a longer ICU and hospital LOS (p < 0.001). No differences in 30-day re-admission rate were found (Table 4).

Outcomes

No differences in the mortality rate at 30 days or one year
were found. The median time to death was shorter in the
infection cohort although not significantly so (41.6 vs.
470 days; p = 0.23). Three patients in the early infection
group died prior to hospital discharge as a result of sepsis
(n = 2) or primary graft dysfunction (PGD) (n = 1). One pa-

Risk Factors for Early Infection

The following variables in the univariable analyses with a
p value <0.1 were entered in a backwards stepwise logistical
regression analysis: LVAD (with and without drive-line infection), ECMO (pre- and post-OHT), delayed chest closure,
and CRRT. This analysis revealed that that pre-OHT LVAD

Table 2. Post-OHT Process-of-Care Variablesa
Variable
Induction therapy
None
Basiliximab
Anti-thymocyte globulin
CRRT
Delayed chest closure
ECMO
Mechanical ventilation duration (d)b
a

Early infection (n = 51)
16
28
7
29
32
9
5.27

(31.4)
(54.9)
(13.7)
(56.9)
(62.7)
(17.6)
( 2.56–11.7)

No early infection (n = 121)
34
68
19
18
31
3
1.68

All values presented as n (%) unless otherwise noted.
Values presented as median (interquartile range).
CRRT = continuous renal replacement therapy; ECMO = extracorporeal membrane oxygenation.

b

(28.1)
(56.2)
(15.7)
(14.9)
(25.6)
( 2.5)
( 0.8–3.39)

p

0.889
<0.001
<0.001
<0.001
<0.001
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Table 3. Organisms Isolateda
Gram negative 39 (58.2%)

Downloaded by Washington Univ from www.liebertpub.com at 07/18/18. For personal use only.

Enterobacter cloacae
Escherichia coli
Klebsiella pneumonia
Serratia marcesens
Pseudomonas
aeruginosa
Haemophilus influenza
Stenotrophomonas
maltophilia
Acinetobacter
calcoaceticusbaumannii
Citrobacter freundii
Enterobacter sp
Moraxella catarrhalis
Prevotella oris

Discussion

Fungi 6 (9.0%)
9
7
5
5
4
2
2

Candida spp.
C. albicans
C. tropicalis
Aspergillus fumigatus
Aspergillus niger
Yeast (unspecified)

3
2
1
1
1
1

Anaerobes 2 (3.0%)
Clostridium difficile

2

1
1
1
1
1

Gram positive 20 (29.9%)
Staphylococcus spp.
S. aureus
S. epidermidis
S. lugdunensis
Beta-hemolytic
Streptococcus Group G
Beta-hemolytic
Streptococcus Group F
Beta-hemolytic
Streptococcus Group C
Brevibacterium spp.
Coryneform bacteria
Enterococcus faecium
Other Enterococcus spp.
Cocci (no speciation)
a

11
8
2
1
1
1
1
1
1
2
1
1

Sixteen patients (31.4%) had polymicrobial cultures.

(AOR 2.53; 95% CI 1.015–6.286; p < 0.046), pre-OHT ECMO
(AOR 14.1; 95% CI 1.38–150.5; p = 0.026), and post-OHT
CRRT (AOR 3.98; 95% CI 1.67–9.52; p = 0.002) were independent risk factors for an early infection (Table 5). Further
analysis assessing the impact of a prior LVAD on the development of an infection was performed. No significant differences in the number of pneumonia, BSI, UTI, or wound
infections were found in patients with and without a LVAD.

This study provides insight into the characteristics of OHT
recipients with an early infection. The incidence of early
infection found in this study (29.7%) is lower than that in
previous reports of infection within 30 days of heart transplantation (48.6%), likely due to the requirement of a positive
culture for inclusion in our study [7]. Although gram-positive
bacteria have been the primary cause of infections in this
patient population historically, one study assessing more than
600 heart transplant recipients noted a P. aeruginosa infection rate as high as 43%, with the most common site of infection being the lungs (35%) [4]. Similarly, gram-negative
organisms comprised the majority of the isolates in our
study (58.2%), with the lungs being the most prevalent site
of infection. Gram-positive infection still was prevalent
(30%) followed by fungal infection (9%). Significantly,
MDR pathogens were present in 47% of patients. Extendedspectrum ESBL-producing gram-negative organisms have
been reported in 2.2% of heart transplant recipients [12],
whereas we noted two ESBL infections (3.9%).
The median time to early infection was less than a week in
our study, with lung infections prevailing at a median of five
days and blood cultures at a median of 1.5 days. In fact, all
patients but one met the infection criteria within 14 days of
transplant, suggesting this is the most critical time period to
prevent post-OHT infection. Montoya et al. [4] report median
times for infectious episodes to be 28 days for mediastinal
incisions, 48 days for bacteremia, and 65 days for pneumonia.
The differences may be attributable to the large percentage of
pre-OHT mechanical circulatory support in our study, as the
infection risks in this patient population are well known.
Our mortality rate in the early post-transplantation period
was less than 5% and was not different at one year, similar to
the findings in other published reports [2,8]. Although the
difference was not statistically significant, it should be recognized that the 30-day mortality rate was 4% in the infection
cohort and 0.8% in the no-infection cohort. The likelihood of
a Type II error in testing this difference is high. In addition,
rejection and re-admission were similar in the two groups.
Mechanical ventilation duration and LOS were longer in the
infection cohort; however, it remains unknown whether this
was a consequence of or a risk factor for infection. It is intuitive to think that patients with pneumonia will require
longer mechanical ventilation. Likewise, patients with any

Table 4. Outcomes of Early Infection Cohort vs. No Early Infection Cohorta
Variable
Death
Median time to death (days)b
At 1 y
At 30 d
Rejection <60 d
Post-OHT intensive care unit length of stay (d)b
Post-OHT hospital length of stay (d) b
30-d re-admission
Infection
Other
a

All values presented as n (%) unless otherwise noted.
Values presented as median (interquartile range).
OHT = orthotopic heart transplantation.

b

Early infection (n = 51)
41.6
3
2
8
14.2
29.8
17
7
10

(13.9–736.6)
( 5.9)
( 3.9)
(15.7)
( 6.8– 21.2)
(17.7– 19.5)
(33.3)
(41.1)
(58.8)

No early infection (n = 121)
470.3
6
1
17
5.6
14.7
42
13
29

(192.3–801.5)
( 5.0)
( 0.8)
( 14.0)
( 3.9– 7.9)
( 11.7– 19.5)
( 34.7)
( 31.0)
( 69.0)

p
0.230
0.726
0.210
0.781
<0.001
<0.001
0.862

INFECTION AFTER HEART TRANSPLANTATION
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Table 5. Multivariate Logistic Regression Analysis
for Predictors of Early Infection
Variable
Pre-OHT LVAD
Pre-OHT LVAD with
drive-line infection
Pre-OHT ECMO
Post-OHT ECMO
Post-OHT delayed
chest closure
Post-OHT CRRT

AOR (95% CI)

p

2.53 (1.015–6.286)
1.16 (0.377–3.54)

0.046
0.799

14.40 (1.38–150.50)
3.05 (0.587–15.80)
1.69 (0.697–4.09)

0.026
0.185
0.246

3.98 (1.670–9.52)

0.002

Downloaded by Washington Univ from www.liebertpub.com at 07/18/18. For personal use only.

Hosmer-Lemes p = 0.99.
AOR = adjusted odds ratio; CI = confidence interval; CRRT = continuous renal replacement therapy; ECMO = extracorporeal membrane
oxygenation; LVAD = left-ventricular assist device; OHT = orthotopic
heart transplantation.

infection may have a longer LOS, with the assumption that
they have a greater severity of illness requiring longer
treatment and monitoring. Regardless, we were unable to
establish causality between these important factors.
Predictors of an early infection in our study included the use
of mechanical circulatory support and the need for acute
CRRT. Induction immunosuppression, renal replacement
therapy, delayed chest closure, and the use of ECMO have
been associated with a possible increase in the risk of fungal
infections in OHT recipients [11,12]. However, these studies
were small and do not addresses whether these factors place
patients at risk for other bacterial infections [10,11,21] Previous LVAD-related infections have been noted to put patients
at risk for more invasive infections after OHT, with continuous
antimicrobial treatment before, during, and after transplantation being associated with fewer relapses [20]. In our study,
more patients in the infection group had histories of drive-line
infections, but this did not remain a predictor of infection by
logistic regression analysis. This finding may suggest that the
presence of an LVAD alone (with or without a previous infection) is a risk factor for post-OHT infection. Although delayed chest closure did not remain a predictor of infection in
our study, it is worth noting that fungal infections occurred in
only three of these patients, whereas gram-negative infections
(72%) prevailed. The three patients with delayed chest closure
who developed a fungal BSI (within 10–16 days) were all
LVAD explants, with one receiving chronic suppressive antibiotics for a median of 80 weeks. Although this may be
important, because of the limited number of fungal infections
and study design limitations, we are unable to make definitive
recommendations on anti-fungal prophylaxis. However,
known risk factors for fungal infection, such as long-term
receipt of antibiotics [22], should be considered when deciding
on prophylaxis in this patient population. Regarding routine
antibiotic prophylaxis, it is worth noting that in our study, 90%
of the susceptibility panels for the gram-negative isolates
showed resistance to our standard intra-operative and perioperative prophylaxis cephalosporin, cefazolin. Accordingly,
the median time to positive culture in this group experiencing
resistance was less than two days. A broader-spectrum cephalosporin with adequate in vitro activity against the most
common organisms cultured, such as cefepime, may be warranted in the early transplant period in these high-risk populations. Non-cephalosporin alternatives such as carbapenems

may be appropriate at centers with higher rates of ESBLproducing organisms. Likewise, centers with lower rates of
AmpC-producing organisms may desire to use b-lactamase–
inhibiting agents, such as piperacillin/tazobactam.
There are several limitations of this study. This was a retrospective cohort investigation and suffers from the potential
biases inherent to this design. The interpretation of positive culture significance, therapeutic management, and patient
outcome depends on the accuracy of the documentation. Additionally, patients treated for culture-negative sepsis or suspected clinical infections were not included. The majority of
the positive cultures were identified during the patient’s stay in
the ICU, and the incidence and impact of an early positive
culture outside of an ICU remains unknown. Furthermore, the
frequency and timing of any previously treated infections was
not assessed. It remains unknown if prior infections, outside of
chronic drive-line infections, increased the risk of post-OHT
infection in this study. In addition, the impact of nasogastric
tube application and receipt of enteral nutrition on the occurrence of pneumonia infections could not be assessed. Finally, as
this study was conducted at a single institution, the results may
not be applicable to other institutions.
In conclusion, this study has provided additional descriptions of the OHT patient population with an infection in the
early post-operative period. Gram-negative organisms accounted for the majority of isolates, with most common sites
of infection being the lungs and blood. Although no statistically significant differences in overall mortality, rejection, or
re-admission rates were seen, a longer LOS and duration of
mechanical ventilation were found in patients with an early
infection. The relative difference in the 30-day mortality rate
may support a modified approach to preventing infection in
higher-risk patients. Previous mechanical support and the need
for acute CRRT may place heart transplant recipients at risk for
an early infection. Evaluation of peri-operative antimicrobial
prophylaxis duration and selection based on an individual
center’s resistance panels may be warranted in these patients.
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